← Eichor
Study identifier: NCT06196697 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

Condition: Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma  ·  Sponsor: Harbin Medical University

PhasePhase 2
Planned participants50
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

The goal of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and anti-tumor activities of cadonilimab in combination with Ivonescimab plus chemotherapy as first-line therapy in adult subjects with HER2 negative、advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.

This description comes directly from the study's public registry record.

Talk to the study team

yanqiao zhang, phD  ·  +86 138 4512 0210  ·  yanqiaozhang@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Harbin Medical University HospitalHarbin, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06196697